Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2021 07:00 ET | Source: uniQure Inc.

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector

~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~ ~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ...
May 10, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress

~ 52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter ~ ~ Announced closing of the global commercialization and license agreement with CSL Behring for...
May 06, 2021 07:00 ET | Source: uniQure Inc.

uniQure announces closing of commercialization and license agreement with CSL Behring

LEXINGTON, Mass. and AMSTERDAM, May 06, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
May 03, 2021 07:05 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in May

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 28, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 26, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 08, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain

LEXINGTON, Mass. and AMSTERDAM, April 08, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
April 05, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~ ~ Company announces plans to initiate a second clinical study of AMT-130 in Europe in the second half of 2021 ~ LEXINGTON, Mass....
April 01, 2021 07:05 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in April

LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
March 29, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program

~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the causeof HCC in HOPE-B pivotal trial ~ ~ Data from investigation submitted to U.S Food and Drug...